ShareSpot: AETC Blog
Halley Cornell, BA
National HIV/AIDS Clinicians' Consultation Center
Nearly 1.4% of the country's incarcerated population -- or about 20,500 state prisoners and 1,500 federal prisoners -- is known to be HIV-positive, according to the most currently available data from the U.S. Department of Justice's Bureau of Justice Statistics. Most of this population contracted HIV prior to incarceration, and some may be engaged in continuous care for the first time upon entering the correctional system. The National HIV/AIDS Clinicians' Consultation Center (NCCC) provides hundreds of clinical consultations each year for healthcare providers working with incarcerated populations in federal, state, and local prisons and jails. In 2012, the NCCC answered 235 calls on the Warmline, 248 on the PEPline, and 7 on the Perinatal HIV Hotline from providers working with incarcerated persons who are HIV-infected, or who may have sustained an exposure to HIV. The Center also works specifically with a team of pharmacist and physician providers for the Federal Bureau of Prisons, providing monthly distance-based consultations and management recommendations for complex or ongoing cases.
Josephine DiLena, RD, BS
François-Xavier Bagnoud Center
School of Nursing, University of Medicine and Dentistry of New Jersey
HIV-infected persons in the U.S. are increasingly overweight and obese with rates of weight excess similar to the general population. Weight excess in the HIV-infected population is often associated with other medical conditions such as hypertension and high cholesterol, and clinicians should consider including weight management programs as part of routine HIV care.¹ Josephine DiLena is a Registered Dietitian practicing at the François-Xavier Bagnoud (FXB) Center Clinic at The University Hospital in Newark, New Jersey. For seven years she has been caring for HIV-infected men, women and children, offering them nutritional guidance to enhance antiretroviral treatment (ART) and other therapies. Over the years, she has witnessed the changes in weight loss and gain among ART users, so we asked her to share what she believes to be most important for HIV providers to keep in mind when discussing nutrition with their patients.
Darunavir Once-Daily Dosing for Children
Tenofovir alafenamide fumarate (TAF) is an investigational prodrug of tenofovir. You will recall that the current tenofovir product, tenofovir disoproxil fumarate (TDF), also is a prodrug; so why are we interested in a new prodrug? This largely has to do with efforts to decrease the toxicity associated with tenofovir.